News stories about SciClone Pharmaceuticals (NASDAQ:SCLN) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. SciClone Pharmaceuticals earned a coverage optimism score of 0.17 on Accern’s scale. Accern also gave media stories about the specialty pharmaceutical company an impact score of 45.2011877090795 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

SciClone Pharmaceuticals (NASDAQ:SCLN) remained flat at $$11.15 during trading hours on Monday. The company’s stock had a trading volume of 2,224,600 shares, compared to its average volume of 444,833. SciClone Pharmaceuticals has a one year low of $8.55 and a one year high of $11.43.

COPYRIGHT VIOLATION NOTICE: This story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another domain, it was illegally copied and reposted in violation of US & international copyright law. The legal version of this story can be read at https://www.thecerbatgem.com/2017/12/18/sciclone-pharmaceuticals-scln-given-daily-coverage-optimism-score-of-0-17.html.

About SciClone Pharmaceuticals

SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.

Insider Buying and Selling by Quarter for SciClone Pharmaceuticals (NASDAQ:SCLN)

Receive News & Stock Ratings for SciClone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciClone Pharmaceuticals and related stocks with our FREE daily email newsletter.